Catalog No.: PC-72606Not For Human Use, Lab Use Only.
AZD9833 (Camizestrant) is an orally bioavailable, highly potent, next-generation selective estrogen receptor degrader (SERD) and antagonist with both EC50 of <1 nM (ERα receptor) in MCF7 cells.
AZD9833 (Camizestrant) is an orally bioavailable, highly potent, next-generation selective estrogen receptor degrader (SERD) and antagonist with both EC50 of <1 nM (ERα receptor) in MCF7 cells.
AZD9833 demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines.
In contrast to AZD9496, AZD9833 does not cause ER agonism in the endometrial carcinoma cell line Ishikawa in vitro and does not cause an increase in the thickness of the endometrium in juvenile rats.
AZD9833 completely suppresses tumor growth in several patient-derived and cell line xenograft models, including models with clinically relevant ESR1 mutations.
